^Smith, WW; Sancilio, LF; Owera-Atepo, JB; Naylor, RJ; Lambert, L (1988). „Zacopride, a potent 5-HT3 antagonist”.The Journal of pharmacy and pharmacology.40 (4): 301—2.PMID2900319.doi:10.1111/j.2042-7158.1988.tb05253.x.
^Lefebvre, H; Contesse, V; Delarue, C; Soubrane, C; Legrand, A; Kuhn, JM; Wolf, LM; Vaudry, H (1993). „Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies”.The Journal of Clinical Endocrinology and Metabolism.77 (6): 1662—6.PMID8263156.doi:10.1210/jc.77.6.1662.
^Young, R; Johnson, DN (1991). „Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice”.European Journal of Pharmacology.201 (2–3): 151—5.PMID1686755.doi:10.1016/0014-2999(91)90338-Q.
^Costall, B; Domeney, AM; Gerrard, PA; Kelly, ME; Naylor, RJ (1988). „Zacopride: anxiolytic profile in rodent and primate models of anxiety”.The Journal of pharmacy and pharmacology.40 (4): 302—5.PMID2900320.doi:10.1111/j.2042-7158.1988.tb05254.x.
^Yamakuni, H; Nakayama, H; Matsui, S; Imazumi, K; Matsuo, M; Mutoh, S (2006). „Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets”.Journal of pharmacological sciences.101 (1): 99—102.PMID16651699.doi:10.1254/jphs.SCJ05007X.
^Carley, DW; Depoortere, H; Radulovacki, M (2001). „R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats”.Pharmacology, Biochemistry, and Behavior.69 (1–2): 283—9.PMID11420096.doi:10.1016/S0091-3057(01)00535-4.
^Meyer, LC; Fuller, A; Mitchell, D (2006). „Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats”.American journal of physiology. Regulatory, integrative and comparative physiology.290 (2): R405—13.PMID16166206.doi:10.1152/ajpregu.00440.2005.